Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Neuromuscular diseases comprise a heterogeneous group of disorders characterized by progressive impairment of muscle function resulting from defects in ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results